Note: Ingredients listed on restricted chemical lists
EC/CAS
215-185-5/1310-73-2
Name of the chemical
sodium hydroxide
Concentration
>=1-<2%
General Information
Version
9.2
Revision date
2025-03-12
Product name
Sodium hydroxide solution c(NaOH) = 0.25 mol/l (0.25 N) Titripur
CAS No.
1310-73-2
1.2.1 Relevant identified uses
Reagent for analysis
Emergency telephone
+44 (0)870 8200418
Icons in SDS
Company Information
Company name
Merck Life Science UK Limited
E-mail address of the competent person responsible for the Safety Data Sheet
TechnicalService@merckgroup.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H290, H315, H319
Hazard statements
Code
Statements
H290
May be corrosive to metals
Section 2
SECTION 2: Hazards identification
2.2 Label elements
Labelling
Signal word
Warning Warning
Hazard statements
H290 May be corrosive to metals. H315 Causes skin irritation. H319 Causes serious eye irritation. none
Precautionary statements
P234 Keep only in original packaging. P264 Wash skin thoroughly after handling. P280 Wear protective gloves/ eye protection/ face protection. P302 + P352 IF ON SKIN: Wash with plenty of water. P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P332 + P313 If skin irritation occurs: Get medical advice/ attention. none
Supplemental label elements
none Reduced Labeling (<= 125 ml) none
Hazard pictograms
none
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher
ECOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
TOXICOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
